Search

Displaying results 2131 - 2140 of 10000 in total
  1. Drug

    2-deoxyglucose

    go.drugbank.com/drugs/DB08831
    Investigational

    Although there are several possible therapeutic indications for 2-deoxyglucose, presently there is no approved indication for 2-deoxyglucose as a therapeutic agent. … The exact mechanisms of action of 2-deoxyglucose is still being investigated, but it is known that in hypoxic cancer cells, 2-deoxyglucose is a glycolysis inhibitor that prevents ATP production and, ultimately

  2. Drug

    Vecuronium

    go.drugbank.com/drugs/DB01339
    ApprovedInvestigational

    A non-depolarizing neuromuscular blocking agent with shorter duration of action than pancuronium.

  3. Drug

    Carglumic acid

    go.drugbank.com/drugs/DB06775
    ApprovedInvestigational

    Carglumic acid was approved by the U.S. Food and Drug Administration (FDA) on 18 March 2010. … Carglumic acid is a drug used for the treatment of hyperammonemia in patients with a deficiency in N-acetyl glutamate synthase.

    Synonyms: N-Carbamylglutamate, N-Carbamyl-L-glutamate
  4. Drug

    Lirentelimab

    go.drugbank.com/drugs/DB16728
    Investigational

    Lirentelimab is under investigation in clinical trial NCT04856891 (A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Duodenitis).

    Synonyms: Recombinant humanized, non-fucosylated IgG1 anti-Siglec-8 monoclonal antibody
  5. Drug

    Seladelpar

    go.drugbank.com/drugs/DB12390
    ApprovedInvestigational

    [L51149] On August 14, 2024, seladelpar was granted accelerated approval by the FDA for the treatment of primary biliary cholangitis,[L51154] which is a condition associated with aberrant bile acid metabolism

  6. Drug

    Adapalene

    go.drugbank.com/drugs/DB00210
    ApprovedInvestigational

    [A193518] Adapalene has similar efficacy but a superior safety profile compared to tretinoin. … [A193518] Differin®, produced by Galderma Labs, was first granted FDA approval on May 31st, 1996, as a 0.1% adapalene topical solution.

  7. Drug

    Metreleptin

    go.drugbank.com/drugs/DB09046
    ApprovedInvestigational

    [L41315] Metreleptin was approved by Health Canada in January 2024 for the same patient population, in addition to patients with partial lipodystrophy.[L49901] … [A263126] These metabolic abnormalities are often aggravated by excessive food intake, which is further aggravated by leptin deficiency, a protein secreted by adipose tissue.

    Synonyms: N-Methionylleptin
  8. Drug

    Xenon Xe-129

    go.drugbank.com/drugs/DB17386
    ApprovedInvestigational

    [Helium-3] (He-3) is the one most commonly used due to its strong signal and favorable safety profile, but its use in other applications has affected its availability. … [L44528] Hyperpolarized Xe-129 is chemically identical to non-polarized Xe-129, and xenon is a clear, colorless, monoatomic, inert, stable, noble gas.[L44523]

  9. Drug

    Ofatumumab

    go.drugbank.com/drugs/DB06650
    ApprovedInvestigational

    [L12612] Ofatumumab works by recognizing antigens that are expressed on the tumour cells in certain cancers; however, the antigen is not tumour-specific and can also be found in normal B-cells. … [A6921] Ofatumumab was first approved by the FDA in 2009.

  10. Drug

    Umifenovir

    go.drugbank.com/drugs/DB13609
    Investigational

    [A191475,A191412] This dual activity may also confer additional protection against viral resistance, as the development of resistance to umifenovir does not appear to be significant. … [A191475] Umifenovir is currently being investigated as a potential treatment and prophylactic agent for COVID-19 caused by SARS-CoV2 infections in combination with both currently available and investigational